AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
oxymetazoline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antihistaminics or local vasoconstrictors, antazoline derivatives | 2032 | 1491-59-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Imidazoline derivative with sympathomimetic activity that stimulates alpha-adrenergic receptors in the arterioles of the nasal mucosa to produce vasoconstriction.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.40 | mg | N |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 11 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.906 | Moderate | 0.66 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 4.519 | Moderate | 0.66 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 5.572 | 10^-6 cm/s | Moderate | 0.66 |
| dh-clint | Dog hepatocyte intrinsic clearance | 3.784 | uL/min/10^6 cells | Moderate | 0.66 |
| dppb | Dog plasma protein binding (% unbound) | 28.950 | % | Moderate | 0.66 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 43.140 | % | Moderate | 0.66 |
| herg | hERG pIC50 | 5.128 | pIC50 | Moderate | 0.66 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.936 | uL/min/10^6 cells | Moderate | 0.66 |
| hlm-clint | Human liver microsomal intrinsic clearance | 6.266 | uL/min/mg protein | Moderate | 0.66 |
| hppb | Human plasma protein binding (% unbound) | 31.570 | % | Moderate | 0.66 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 52 | |||
| kinase-selectivity-class | BRAF,GRK2,PDK4 | 3 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 4.227 | Moderate | 0.66 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 24.774 | Moderate | 0.66 | |
| mppb | Mouse plasma protein binding (% unbound) | 21.320 | Moderate | 0.66 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 8.091 | Moderate | 0.66 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 37.170 | % | Moderate | 0.66 |
| rh-clint | Rat hepatocyte intrinsic clearance | 22.491 | uL/min/10^6 cells | Moderate | 0.66 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 58.050 | % | Moderate | 0.66 |
| rppb | Rat plasma protein binding (% unbound) | 28.240 | % | Moderate | 0.66 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 847.227 | uM | Moderate | 0.66 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 30, 1986 | FDA | BAYER HEALTHCARE LLC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Eye irritation | 104.87 | 16.91 | 46 | 4778 | 33932 | 90589691 |
| Ocular hyperaemia | 79.85 | 16.91 | 38 | 4786 | 33760 | 90589863 |
| Mydriasis | 72.46 | 16.91 | 28 | 4796 | 14984 | 90608639 |
| Swelling of eyelid | 56.61 | 16.91 | 18 | 4806 | 5436 | 90618187 |
| Vision blurred | 50.65 | 16.91 | 44 | 4780 | 110249 | 90513374 |
| Trigemino-cardiac reflex | 44.93 | 16.91 | 7 | 4817 | 72 | 90623551 |
| Nasal congestion | 43.89 | 16.91 | 36 | 4788 | 83378 | 90540245 |
| Cerebral vasoconstriction | 40.33 | 16.91 | 10 | 4814 | 1224 | 90622399 |
| Lacrimation increased | 34.09 | 16.91 | 20 | 4804 | 27042 | 90596581 |
| Hypervolaemia | 28.16 | 16.91 | 19 | 4805 | 32738 | 90590885 |
| Abnormal sensation in eye | 26.78 | 16.91 | 8 | 4816 | 1963 | 90621660 |
| Electrocardiogram ST segment depression | 26.60 | 16.91 | 9 | 4815 | 3294 | 90620329 |
| Dry eye | 26.34 | 16.91 | 23 | 4801 | 57908 | 90565715 |
| Blood bilirubin unconjugated decreased | 23.92 | 16.91 | 4 | 4820 | 66 | 90623557 |
| Urine albumin/creatinine ratio abnormal | 21.60 | 16.91 | 4 | 4820 | 121 | 90623502 |
| Nasal discomfort | 18.70 | 16.91 | 8 | 4816 | 5540 | 90618083 |
| Amaurosis | 18.69 | 16.91 | 5 | 4819 | 825 | 90622798 |
| Creatinine urine decreased | 17.98 | 16.91 | 4 | 4820 | 306 | 90623317 |
| Transferrin decreased | 16.99 | 16.91 | 4 | 4820 | 394 | 90623229 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Epistaxis | 28.99 | 16.85 | 28 | 2700 | 66798 | 42551809 |
| Vision blurred | 22.34 | 16.85 | 22 | 2706 | 53677 | 42564930 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Mydriasis | 68.66 | 15.90 | 31 | 6463 | 22126 | 110560679 |
| Eye irritation | 62.14 | 15.90 | 33 | 6461 | 33419 | 110549386 |
| Ocular hyperaemia | 59.86 | 15.90 | 34 | 6460 | 39252 | 110543553 |
| Vision blurred | 44.66 | 15.90 | 46 | 6448 | 128976 | 110453829 |
| Swelling of eyelid | 43.81 | 15.90 | 16 | 6478 | 6637 | 110576168 |
| Hypervolaemia | 40.69 | 15.90 | 29 | 6465 | 49431 | 110533374 |
| Cerebral vasoconstriction | 37.41 | 15.90 | 10 | 6484 | 1491 | 110581314 |
| Epistaxis | 37.24 | 15.90 | 42 | 6452 | 130330 | 110452475 |
| Lacrimation increased | 34.71 | 15.90 | 22 | 6472 | 30928 | 110551877 |
| Trigemino-cardiac reflex | 31.77 | 15.90 | 7 | 6487 | 464 | 110582341 |
| Nasal congestion | 30.37 | 15.90 | 33 | 6461 | 98249 | 110484556 |
| Nasal discomfort | 23.53 | 15.90 | 10 | 6484 | 6171 | 110576634 |
| Blood bilirubin unconjugated decreased | 23.15 | 15.90 | 4 | 6490 | 73 | 110582732 |
| Electrocardiogram ST segment depression | 21.34 | 15.90 | 9 | 6485 | 5452 | 110577353 |
| Dry eye | 21.32 | 15.90 | 21 | 6473 | 55772 | 110527033 |
| Urine albumin/creatinine ratio abnormal | 20.40 | 15.90 | 4 | 6490 | 149 | 110582656 |
| Toxicity to various agents | 18.54 | 15.90 | 3 | 6491 | 480552 | 110102253 |
| Deafness permanent | 17.64 | 15.90 | 5 | 6489 | 926 | 110581879 |
| Rebound nasal congestion | 17.15 | 15.90 | 3 | 6491 | 59 | 110582746 |
| Creatinine urine decreased | 16.89 | 15.90 | 4 | 6490 | 366 | 110582439 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D11AX27 | DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Other dermatologicals |
| ATC | R01AA05 | RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Sympathomimetics, plain |
| ATC | R01AB07 | RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Sympathomimetics, combinations excl. corticosteroids |
| ATC | S01GA04 | SENSORY ORGANS OPHTHALMOLOGICALS DECONGESTANTS AND ANTIALLERGICS Sympathomimetics used as decongestants |
| FDA CS | M0461078 | Imidazolines |
| FDA PE | N0000009908 | Vasoconstriction |
| MeSH PA | D000316 | Adrenergic alpha-Agonists |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D013566 | Sympathomimetics |
| MeSH PA | D014662 | Vasoconstrictor Agents |
| MeSH PA | D014663 | Nasal Decongestants |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D019141 | Respiratory System Agents |
| FDA PE | N0000175651 | Increased Sympathetic Activity |
| CHEBI has role | CHEBI:35524 | sympathomimetic agent |
| CHEBI has role | CHEBI:35569 | α-adrenergic agonist |
| CHEBI has role | CHEBI:50514 | vasoconstrictor agent |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| CHEBI has role | CHEBI:77715 | nasal decongestant |
| FDA EPC | N0000192562 | Vasoconstrictor |
Related Drugs by ATC class:
D11AX Other dermatologicals 20 drugs
R01AA Sympathomimetics, plain 13 drugs
R01AB Sympathomimetics, combinations excl. corticosteroids 6 drugs
S01GA Sympathomimetics used as decongestants 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Nasal discharge | indication | 64531003 | |
| Nasal congestion | indication | 68235000 | |
| Red eye | indication | 75705005 | |
| Local anesthesia | indication | 386761002 | |
| Persistent erythema of skin | indication | 420356000 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Pain in eye | contraindication | 41652007 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Arteriosclerotic vascular disease | contraindication | 72092001 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Eye infection | contraindication | 128351009 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Visual impairment | contraindication | 397540003 | |
| Disorder of coronary artery | contraindication | 414024009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.6 | acidic |
| pKa2 | 10.99 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1% | RHOFADE | MAYNE PHARMA | N208552 | Jan. 18, 2017 | RX | CREAM | TOPICAL | 7812049 | May 2, 2028 | TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM |
| 0.1MG/SPRAY;6MG/SPRAY | KOVANAZE | ST RENATUS | N208032 | June 29, 2016 | RX | SPRAY, METERED | NASAL | 8580282 | April 2, 2030 | METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH |
| 0.1MG/SPRAY;6MG/SPRAY | KOVANAZE | ST RENATUS | N208032 | June 29, 2016 | RX | SPRAY, METERED | NASAL | 9308191 | April 2, 2030 | METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH |
| 0.1% | UPNEEQ | RVL PHARMS | N212520 | July 8, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 10912765 | Aug. 26, 2031 | METHOD OF TREATING BLEPHAROPTOSIS |
| 0.1% | UPNEEQ | RVL PHARMS | N212520 | July 8, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 8357714 | Aug. 26, 2031 | METHOD OF TREATING BLEPHAROPTOSIS |
| 0.1% | UPNEEQ | RVL PHARMS | N212520 | July 8, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 9867808 | Aug. 26, 2031 | METHOD OF TREATING BLEPHAROPTOSIS |
| 1% | RHOFADE | MAYNE PHARMA | N208552 | Jan. 18, 2017 | RX | CREAM | TOPICAL | 10335391 | June 11, 2035 | ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM, WHERE THE PATIENT EXPERIENCES NO REBOUND OR WORSENING OF FACIAL ERYTHEMA POST-TREATMENT |
| 1% | RHOFADE | MAYNE PHARMA | N208552 | Jan. 18, 2017 | RX | CREAM | TOPICAL | 10751325 | June 11, 2035 | ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS |
| 1% | RHOFADE | MAYNE PHARMA | N208552 | Jan. 18, 2017 | RX | CREAM | TOPICAL | 11517560 | June 11, 2035 | ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN FEMALE ADULTS |
| 1% | RHOFADE | MAYNE PHARMA | N208552 | Jan. 18, 2017 | RX | CREAM | TOPICAL | 12350255 | June 11, 2035 | ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN FEMALE ADULTS |
| 1% | RHOFADE | MAYNE PHARMA | N208552 | Jan. 18, 2017 | RX | CREAM | TOPICAL | 9974773 | June 11, 2035 | ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM |
| 0.1% | UPNEEQ | RVL PHARMS | N212520 | July 8, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 10799481 | Dec. 16, 2039 | METHOD OF TREATING BLEPHAROPTOSIS |
| 0.1% | UPNEEQ | RVL PHARMS | N212520 | July 8, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 10940138 | Dec. 16, 2039 | METHOD OF TREATING BLEPHAROPTOSIS |
| 0.1% | UPNEEQ | RVL PHARMS | N212520 | July 8, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 11324722 | Dec. 16, 2039 | METHOD OF TREATING BLEPHAROPTOSIS |
| 0.1% | UPNEEQ | RVL PHARMS | N212520 | July 8, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 11701343 | Dec. 16, 2039 | METHOD OF TREATING BLEPHAROPTOSIS |
| 0.1% | UPNEEQ | RVL PHARMS | N212520 | July 8, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 12648930 | Dec. 16, 2039 | METHOD OF TREATING BLEPHAROPTOSIS |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-1A adrenergic receptor | GPCR | AGONIST | Ki | 8.20 | IUPHAR | SCIENTIFIC LITERATURE | |||
| Alpha-2B adrenergic receptor | GPCR | AGONIST | Ki | 6.20 | IUPHAR | SCIENTIFIC LITERATURE | |||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.59 | PDSP | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.83 | PDSP | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | AGONIST | Ki | 6.80 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.11 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.34 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 6.02 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 9.52 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | Ki | 9.40 | CHEMBL | |||||
| Alpha-2C adrenergic receptor | GPCR | AGONIST | Ki | 9 | CHEMBL | ||||
| Cytochrome P450 2D6 | Enzyme | IC50 | 6.70 | DRUG MATRIX | |||||
| Alpha-1D adrenergic receptor | GPCR | AGONIST | Ki | 6.40 | IUPHAR | ||||
| Alpha-1B adrenergic receptor | GPCR | AGONIST | Ki | 6.50 | IUPHAR | ||||
| Alpha-2A adrenergic receptor | GPCR | AGONIST | Ki | 9.54 | CHEMBL | ||||
| Nischarin | Membrane receptor | Ki | 8.21 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1E | GPCR | Ki | 6.38 | PDSP | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 8.49 | DRUG MATRIX | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 6.16 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 9.04 | DRUG MATRIX | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 8.19 | CHEMBL | |||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 6.48 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 8.25 | CHEMBL | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 7.88 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 7.68 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 8.82 | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 6.69 | CHEMBL | |||||
| Adrenergic receptor alpha-2 | GPCR | Ki | 8.72 | CHEMBL | |||||
| Alpha-2 adrenergic receptor | GPCR | Ki | 7.48 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019463 | VUID |
| N0000147584 | NUI |
| D01022 | KEGG_DRUG |
| 2315-02-8 | SECONDARY_CAS_RN |
| 4019462 | VANDF |
| 4019463 | VANDF |
| C0030071 | UMLSCUI |
| CHEBI:7862 | CHEBI |
| J5C | PDB_CHEM_ID |
| CHEMBL762 | ChEMBL_ID |
| CHEMBL1200791 | ChEMBL_ID |
| DB00935 | DRUGBANK_ID |
| D010109 | MESH_DESCRIPTOR_UI |
| 4636 | PUBCHEM_CID |
| 124 | IUPHAR_LIGAND_ID |
| 1400 | INN_ID |
| 8VLN5B44ZY | UNII |
| 106101 | RXNORM |
| 44349 | MMSL |
| 5218 | MMSL |
| 5411 | MMSL |
| 5424 | MMSL |
| 001810 | NDDF |
| 004728 | NDDF |
| 29129004 | SNOMEDCT_US |
| 387158001 | SNOMEDCT_US |
| 9910008 | SNOMEDCT_US |
| 8VLN5B44ZY | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Theraflu Severe Congestion Relief Cooling Nasal Mist | HUMAN OTC DRUG LABEL | 1 | 0067-0109 | SPRAY | 0.50 mg | NASAL | OTC Monograph Drug | 14 sections |
| Theraflu Severe Congestion Relief Nasal Mist | HUMAN OTC DRUG LABEL | 1 | 0067-0110 | SPRAY | 0.50 mg | NASAL | OTC Monograph Drug | 14 sections |
| Good Sense Nasal | HUMAN OTC DRUG LABEL | 1 | 0113-0304 | SPRAY | 0.50 mg | NASAL | OTC Monograph Drug | 14 sections |
| good sense nasal | HUMAN OTC DRUG LABEL | 1 | 0113-0388 | SPRAY, METERED | 0.05 g | NASAL | OTC Monograph Drug | 14 sections |
| good sense nasal | HUMAN OTC DRUG LABEL | 1 | 0113-6200 | SPRAY | 0.05 g | NASAL | OTC Monograph Drug | 14 sections |
| Anefrin NasalOriginal | HUMAN OTC DRUG LABEL | 1 | 0363-0304 | SPRAY | 0.05 g | NASAL | OTC Monograph Drug | 14 sections |
| No Drip Nasal Mist | HUMAN OTC DRUG LABEL | 1 | 0363-2303 | LIQUID | 50 mg | NASAL | OTC Monograph Drug | 13 sections |
| Severe Sinus Relief Mist | HUMAN OTC DRUG LABEL | 1 | 0363-2305 | LIQUID | 50 mg | NASAL | OTC Monograph Drug | 13 sections |
| No Drip Nasal Mist | HUMAN OTC DRUG LABEL | 1 | 0363-2307 | LIQUID | 50 mg | NASAL | OTC Monograph Drug | 12 sections |
| No Drip Severe Anefrin Nasal | HUMAN OTC DRUG LABEL | 1 | 0363-2350 | SPRAY | 50 mg | NASAL | OTC Monograph Drug | 12 sections |
| Walgreens Moisturizing Ultra Fine Mist with Aloe | HUMAN OTC DRUG LABEL | 1 | 0363-2355 | SPRAY | 50 mg | NASAL | OTC Monograph Drug | 14 sections |
| Nasal MistWalgreens | HUMAN OTC DRUG LABEL | 1 | 0363-7000 | LIQUID | 0.05 g | TOPICAL | OTC monograph final | 8 sections |
| Severe Congestion Nasal no dripWalgreens | HUMAN OTC DRUG LABEL | 1 | 0363-7001 | LIQUID | 0.05 g | TOPICAL | OTC monograph final | 9 sections |
| Maximum Strenth Nasal | HUMAN OTC DRUG LABEL | 1 | 0363-7003 | LIQUID | 0.05 g | TOPICAL | OTC monograph final | 7 sections |
| Extra Moisturizing No Drip NasalWalgreens | HUMAN OTC DRUG LABEL | 1 | 0363-7004 | LIQUID | 0.05 g | TOPICAL | OTC monograph final | 7 sections |
| Original No Drip NasalWalgreens | HUMAN OTC DRUG LABEL | 1 | 0363-7005 | LIQUID | 0.05 g | TOPICAL | OTC monograph final | 7 sections |
| Walgreen | HUMAN OTC DRUG LABEL | 1 | 0363-7151 | SPRAY | 0.05 g | NASAL | OTC Monograph Drug | 13 sections |
| Major Nasal Decongestant | HUMAN OTC DRUG LABEL | 1 | 0904-7427 | SPRAY | 0.50 mg | NASAL | OTC Monograph Drug | 14 sections |
| Major Nasal Decongestant | HUMAN OTC DRUG LABEL | 1 | 0904-7435 | SPRAY | 0.50 mg | NASAL | OTC Monograph Drug | 12 sections |
| 7 Select Original Nasal | HUMAN OTC DRUG LABEL | 1 | 10202-849 | SPRAY | 0.05 g | NASAL | OTC monograph final | 11 sections |
| Zicam Extreme Congestion Relief | HUMAN OTC DRUG LABEL | 1 | 10237-464 | SPRAY | 0.50 mg | NASAL | OTC Monograph Drug | 14 sections |
| Zicam Intense Sinus Relief | HUMAN OTC DRUG LABEL | 1 | 10237-471 | SPRAY | 0.50 mg | NASAL | OTC Monograph Drug | 15 sections |
| Afrin NoDrip Allergy Sinus Night | HUMAN OTC DRUG LABEL | 1 | 11523-0034 | SPRAY | 0.50 mg | NASAL | OTC Monograph Drug | 14 sections |
| Afrin Allergy Sinus Nasal | HUMAN OTC DRUG LABEL | 1 | 11523-0073 | SPRAY | 0.50 g | NASAL | OTC Monograph Drug | 14 sections |
| Children Afrin No Drip Extra Moisturizing Stuffy Nose Pump MistStuffy Nose Pump Mist | HUMAN OTC DRUG LABEL | 1 | 11523-0090 | SPRAY, METERED | 0.05 g | NASAL | OTC Monograph Drug | 11 sections |
| Children Afrin Extra Moisturizing Stuffy Nose Pump MistStuffy Nose Pump Mist | HUMAN OTC DRUG LABEL | 1 | 11523-0091 | SPRAY, METERED | 0.03 g | NASAL | OTC Monograph Drug | 11 sections |
| AfrinOriginal Pump Mist | HUMAN OTC DRUG LABEL | 1 | 11523-1159 | SPRAY, METERED | 0.05 g | NASAL | OTC Monograph Drug | 15 sections |
| Afrin No Drip NightChamomile | HUMAN OTC DRUG LABEL | 1 | 11523-1160 | SPRAY, METERED | 0.50 mg | NASAL | OTC Monograph Drug | 13 sections |
| AfrinOriginal | HUMAN OTC DRUG LABEL | 1 | 11523-1167 | SPRAY | 0.05 g | NASAL | OTC Monograph Drug | 15 sections |
| Afrin Original Nasal | HUMAN OTC DRUG LABEL | 1 | 11523-1168 | SPRAY | 0.05 g | NASAL | OTC Monograph Drug | 14 sections |